Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs MasterCard Inc (MA) Price & Performance

AbCellera Biologics IncTrade
MasterCard IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs MasterCard Inc — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.85B), while MasterCard Inc trades at $561.9 (market cap $493.34B). The key difference: MasterCard Inc is far larger — about 173.1× AbCellera Biologics Inc's market cap, and MasterCard Inc pays a 0.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLMA
Market Cap
$2.85B$493.34B
Sector
HealthConsumer Cyclical
52-Week High
$9.76$598.96
52-Week Low
$2.78$471.55
Enterprise Value
$2.45B$506.38B
Volume
4,635,698
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

MasterCard Inc

Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.

The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA